ImClone Systems Incorporated and Bristol-Myers Squibb Company Erbitux Extends Head, Neck Cancer Survival in Study Conducted by Merck KGaA in Germany

DOW -- ImClone Systems Inc. (IMCL) and Bristol-Myers Squibb Co. (BMY) said a Phase 3 trial of Erbitux showed that adding the blockbuster cancer drug to platinum- based chemotherapy improved survival rates in patients with head and neck cancer. The results were published in the New England Journal of Medicine.